Detalhe da pesquisa
1.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
2.
Luspatercept for the treatment of anaemia in non-transfusion-dependent ß-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Lancet Haematol
; 9(10): e733-e744, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007538
3.
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With ß-Thalassemia.
J Clin Pharmacol
; 61(1): 52-63, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696522
4.
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
CPT Pharmacometrics Syst Pharmacol
; 9(7): 395-404, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602651
5.
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
Kidney Int Rep
; 4(11): 1585-1597, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31891000
6.
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Leukemia
; 37(11): 2314-2318, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752285